iSono Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
iSono Health is a medical device company building a portable, AI-powered breast ultrasound scanner designed to make breast cancer screening accessible in low-resource settings. HQ: San Francisco.
About
iSono Health is a medical device company developing an automated, portable breast ultrasound system that uses AI to perform and interpret whole-breast 3D scans without requiring a trained sonographer. The company's ATUSA (Automated Tissue and Ultrasound Analysis) device is designed as a wearable bra-form factor that conducts a complete breast ultrasound scan autonomously, with AI algorithms analyzing the resulting images to detect potential abnormalities. The device targets two large unmet needs: mammography has significant limitations for women with dense breast tissue (where ultrasound is superior), and ultrasound screening is currently limited by the shortage of trained sonographers needed to perform and interpret scans.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.